A  Food and Drug Administration (FDA) advisory board has given a “thumbs-up” to GlaxoSmithKline’s new epilepsy drug Potiga (ezogabine), saying three clinical trials with patients taking the drug show that it effectively controls seizures when used as an add-on treatment in certain epilepsy patients. The main safety concern with Potiga is urinary side effects, which 11 members of the advisory panel said could be mitigated by patient monitoring. Two advisors abstained from voting on that issue.

Potiga is designed to treat adults with partial onset seizures who aren’t adequately treated with other medications. Reported side effects include inability to urinate, dizziness and fatigue. The FDA is not required to follow the recommendation of its advisory board, however it usually does. If approved for marketing in the United States, Potiga stands to make millions in a market that brought in about $13 billion in global sales last year alone.

Seventeen AEDs are FDA-approved for the treatment of seizures, yet one-third of epileptics cannot control their disorders with the medications currently available. Medications also carry side effects that can be harmful for neurological patients who tend to be more sensitive to inactive ingredients and subtleties between brand name and generic formulations of the same drug. If approved, Potiga would be used as a second-line treatment for patients whose seizures are not adequately controlled with currently available AEDs.

Potiga was developed through a partnership between GlaxoSmithKline and Valeant Pharmaceuticals International. Valeant is being acquired by Canadian pharmaceutical firm Biovail Corp., a deal expected to close by the end of 2010. 



We're here to help!

We live by our creed of "helping those who need it most" and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked    may be required for submission.
  1. I'm an attorney

Generic drug savings may come at a price

Think generic medications are just the same as their brand name equivalents? Think again. Generics may...

New iPhone app helps epileptics monior seizures,...

People living with epilepsy can now keep a diary of their seizures on their iPhone, thanks to the new...

Switching from Keppra to generic can make you sick

Switching from brand name Keppra to generic Keppra (levetiracetam) to treat her epileptic seizures made...

Experimental SmartWatch offers peace of mind to...

A fully functional prototype of a wristwatch-style device that can detect myoclonic and grand mal...

Free toolkit available to parents of children...

Parents of children diagnosed with epilepsy have the daunting responsibility of helping their child...

Approval of GlaxoSmithKline, Valeant new epilepsy drug...

Despite a "thumbs-up" from a Food and Drug Administration (FDA) advisory panel on GlaxoSmithKline and...

Impressed with the Beasley Allen staff

I am very impressed with the Beasley Allen staff. They were very courteous and patiently explained the aspects of my claim in a way I could understand. If I ever have any need of an attorney in the future I will turn to Beasley Allen.

—Philip